膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察

发布时间：2018-09-11 19:06

【摘要】：目的:观察膦甲酸钠联合重组人干扰素α2b治疗宫颈人乳头瘤病毒(HPV)持续感染的临床疗效。方法:选取宫颈HPV持续感染患者65例,按照随机数字表法分为治疗组(n=35)和对照组(n=30)。两组患者均给予重组人干扰素α2b栓10万IU,qod(睡前),治疗时间为3个月;治疗组患者在此基础上给予膦甲酸钠氯化钠注射液250 m L,ivgtt,qd,治疗时间为14 d。观察两组患者根据HPV病毒载量判定的疗效、HPV转阴率、宫颈炎评分、根据宫颈炎评分改善率判定的疗效及不良反应发生情况。结果:治疗组患者根据HPV病毒载量判定的总有效率(94.29%)明显高于对照组(76.67%),差异有统计学意义(P0.05);治疗组患者HPV转阴率(77.14%)明显高于对照组(36.67%),差异有统计学意义(P0.05)。两组患者宫颈炎评分均较治疗前明显降低,且治疗组[(1.49±0.70)分]明显低于对照组[(1.97±0.89)分],差异均有统计学意义(P0.05);治疗组患者根据宫颈炎评分改善率判定的总有效率(88.57%)明显高于对照组(73.33%),差异有统计学意义(P0.05)。两组患者治疗过程中均未见不良反应发生。结论:膦甲酸钠联合重组人干扰素α2b能有效抑制HPV病毒复制、提高HPV转阴率、缓解宫颈炎症状,且安全性较高。
[Abstract]:Objective: to observe the clinical effect of phosphonium formate combined with recombinant human interferon 伪 2b in the treatment of persistent cervix human papillomavirus (HPV) infection. Methods: 65 patients with persistent cervical HPV infection were randomly divided into treatment group (n = 35) and control group (n = 30). The patients in both groups were treated with recombinant human interferon 伪 2b suppository for 100000 IU,qod (before bedtime) for 3 months, and patients in the treatment group were treated with phosphonium sodium chloride injection 250ml iv gttttqd for 14 days. To observe the curative effect of the two groups according to the viral load of HPV and the negative rate of HPV, the score of cervicitis, the curative effect according to the improvement rate of the score of cervicitis and the occurrence of adverse reactions. Results: the total effective rate (94.29%) of HPV viral load in the treatment group was significantly higher than that in the control group (76.67%), the difference was statistically significant (P0.05), and the negative rate of HPV in the treatment group (77.14%) was significantly higher than that in the control group (36.67%) (P0.05). The score of cervicitis in both groups was significantly lower than that before treatment. The treatment group [(1.49 卤0.70) score] was significantly lower than the control group [(1.97 卤0.89) score], the difference was statistically significant (P0.05), the total effective rate of the treatment group according to the cervicitis score improvement rate (88.57%) was significantly higher than that of the control group (73.33%), the difference was statistically significant (P0.05). There were no adverse reactions in both groups. Conclusion: phosphonium formate combined with recombinant human interferon 伪 2b can effectively inhibit the replication of HPV virus, increase the negative rate of HPV, relieve the symptoms of cervicitis, and have high safety.
【作者单位】：山东大学第二医院妇产科;
【分类号】：R737.33

【相似文献】